Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

206 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Pro-tumor Tfh2 cells induce detrimental IgG4 production and PGE2-dependent IgE inhibition in pancreatic cancer.
De Monte L, Clemente F, Ruggiero E, Pini R, Ceraolo MG, Schiavo Lena M, Balestrieri C, Lazarevic D, Belfiori G, Crippa S, Balzano G, Falconi M, Doglioni C, Bonini C, Reni M, Protti MP. De Monte L, et al. Among authors: balzano g. EBioMedicine. 2023 Nov;97:104819. doi: 10.1016/j.ebiom.2023.104819. Epub 2023 Sep 28. EBioMedicine. 2023. PMID: 37776595 Free PMC article.
Gemcitabine versus cisplatin, epirubicin, fluorouracil, and gemcitabine in advanced pancreatic cancer: a randomised controlled multicentre phase III trial.
Reni M, Cordio S, Milandri C, Passoni P, Bonetto E, Oliani C, Luppi G, Nicoletti R, Galli L, Bordonaro R, Passardi A, Zerbi A, Balzano G, Aldrighetti L, Staudacher C, Villa E, Di Carlo V. Reni M, et al. Among authors: balzano g. Lancet Oncol. 2005 Jun;6(6):369-76. doi: 10.1016/S1470-2045(05)70175-3. Lancet Oncol. 2005. PMID: 15925814 Clinical Trial.
Raltitrexed-eloxatin salvage chemotherapy in gemcitabine-resistant metastatic pancreatic cancer.
Reni M, Pasetto L, Aprile G, Cordio S, Bonetto E, Dell'Oro S, Passoni P, Piemonti L, Fugazza C, Luppi G, Milandri C, Nicoletti R, Zerbi A, Balzano G, Di Carlo V, Brandes AA. Reni M, et al. Among authors: balzano g. Br J Cancer. 2006 Mar 27;94(6):785-91. doi: 10.1038/sj.bjc.6603026. Br J Cancer. 2006. PMID: 16508631 Free PMC article. Clinical Trial.
PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) regimen as second-line therapy in patients with progressive or recurrent pancreatic cancer after gemcitabine-containing chemotherapy.
Reni M, Cereda S, Mazza E, Passoni P, Nicoletti R, Balzano G, Zerbi A, Arcidiacono PG, Staudacher C, Di Carlo V. Reni M, et al. Among authors: balzano g. Am J Clin Oncol. 2008 Apr;31(2):145-50. doi: 10.1097/COC.0b013e31814688f7. Am J Clin Oncol. 2008. PMID: 18391598 Clinical Trial.
XELIRI or FOLFIRI as salvage therapy in advanced pancreatic cancer.
Cereda S, Reni M, Rognone A, Ghidini M, Belli C, Longoni S, Fugazza C, Brioschi M, Nicoletti R, Balzano G, Passoni P, Villa E. Cereda S, et al. Among authors: balzano g. Anticancer Res. 2010 Nov;30(11):4785-90. Anticancer Res. 2010. PMID: 21115942
206 results